-
Sacubitril Hemicalcium
API’s Name Indication Specification US DMF EU DMF CEP Sacubitril Hemicalcium In-House -
Sofosbuvir
API’s Name Indication Specification US DMF EU DMF CEP Sofosbuvir HCV In-House 32048 √ -
Ribociclib 1374639-75-4
API’s Name Indication Innovator Patent Expiry Date(The U.S) Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
PharmaceuticalsJun.27, 2028 -
Rivaroxaban
API’s Name Indication Specification US DMF EU DMF CEP Rivaroxaban Anticoagulant In-House TDP -
Rosuvastatin Calcium
API’s Name Indication Specification US DMF EU DMF CEP Rosuvastatin Calcium Hypercholesterolemia In-House/CEP 20705 √ CEP2015-240 -
Pitavastatin Calcium
API’s Name Indication Specification US DMF EU DMF CEP Pitavastatin Calcium Hypercholesterolemia In-House -
Pregabalin
API’s Name Indication Specification US DMF EU DMF CEP Pregabalin Epilepsy/Neuralgia In-House/EP 22223 √ CEP2016-141 -
Obeticholic Acid
API’s Name Indication Specification US DMF EU DMF CEP Obeticholic Acid Biliary cholangitis In-House -
Niraparib 1038915-60-4
API’s Name Indication Innovator Patent Expiry Date(The U.S) Niraparib 1038915-60-4 Ovarian/Fallopian,tube/primary peritoneal cancer Tesaro Jan.8, 2028 -
Ledipasvir Actone /PVP
API’s Name Indication Specification US DMF EU DMF CEP Ledipasvir Actone /PVP HCV In-House √ -
LCZ696(Sacubitril + Valsartan)
API’s Name Indication Specification US DMF EU DMF CEP LCZ696(Sacubitril + Valsartan) Heart failure In-House √ -
Lenalidomide
API’s Name Indication Specification US DMF EU DMF CEP Lenalidomide Oncology drug In-House 31804 √